Tag: https://www.bio.org/events/bio-international-convention
The House Energy and Commerce Health Subcommittee held a hearing entitled “Innovation Saves Lives: Evaluating Medicare Coverage Pathways for Innovative Drugs, Medical Devices, and Technology,” focusing on how the Centers for Medicare & Medicaid Services (CMS) defines “reasonable and necessary” criteria for Medicare coverage, the recent national coverage determination (NCD) policy for Alzheimer’s disease drugs, […]
It’s a big week for the Pandemic All-Hazards Preparedness Act (PAHPA)…and the biotech and biodefense industry is watching … source
In a big week for reauthorization of the Pandemic All Hazards and Preparedness Act (PAHPA), versions of the legislation were approved by a House committee on July 19 and a Senate committee on July 20. Here’s what happened and why it matters. PAHPA establishes measures to prepare for the next pandemic and “allows us to […]
Rep. Scott Peters (D-CA) criticized the PAHPA bill for not including the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, of which he is one of the House sponsors. The Senate sponsors of the bill to address antimicrobial resistance have also been pushing for its inclusion in PAHPA, which now seems unlikely. July 20, […]
The state legislatures have been as busy as ever in 2023—especially in the biotech sector. Now, as many legislatures across the country are going into recess, it is a perfect time to take the temperature of the waters during this year’s US state legislative sessions. BIO’s Vice President of State Government Affairs, Patrick Plues, talks […]